Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

The Long-term Effect of Superselective Adrenal Arterial Embolization and Medical Treatment for Primary Aldosteronism on Cardiorenovascular Protection, Blood Pressure, and the Endocrinological Profile.

NCT05262660 is registered in ClinicalTrials.gov with First Affiliated Hospital of Chengdu Medical College as lead sponsor.

NCT NCT05262660
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05262660 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
The Long-term Effect of Superselective Adrenal Arterial Embolization and Medical Treatment for Primary Aldosteronism on Cardiorenovascular Protection, Blood Pressure, and the Endocrinological Profile.
Lead sponsor
First Affiliated Hospital of Chengdu Medical College
Phase
Observational
Overall status
Unknown status
Start date
April 1, 2022
Completion date
January 1, 2025
Enrollment
400 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

primary aldosteronism